Loading
A phase 2 trial of Parsaclisib, Ruxolitinib and Ibrutinib in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) is a phase 2 interventional study registered as NCT04509700 by Incyte Corporation, with 112 participants enrolled, started 2020-08-03 and due to reach its primary completion in 2026-11-05. Interventions recorded: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib and parsaclisib + ibrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Incyte, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Incyte, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ibrutinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ruxolitinib and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Incyte and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/